{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:13:38Z","timestamp":1779329618885,"version":"3.51.4"},"reference-count":27,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,8,15]]},"DOI":"10.2169\/internalmedicine.0463-17","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T22:26:44Z","timestamp":1520548004000},"page":"2413-2416","source":"Crossref","is-referenced-by-count":6,"title":["Rhabdomyolysis Induced by Isoniazid in a Patient with Rheumatoid Arthritis and End-stage Renal Disease: A Case Report and Review of the Literature"],"prefix":"10.2169","volume":"57","author":[{"given":"Toshihiko","family":"Komai","sequence":"first","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Sumitomo","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuzo","family":"Teruya","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keishi","family":"Fujio","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Winthrop KL, Chiller T. Preventing and treating biologic-associated opportunistic infections. Nat Rev Rheumatol 5: 405-410, 2009.","DOI":"10.1038\/nrrheum.2009.105"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. McClintock AH, Eastment M, McKinney CM, et al. Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine. BMC Infect Dis 17: 146, 2017.","DOI":"10.1186\/s12879-017-2245-8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161: S221-S247, 2000.","DOI":"10.1164\/ajrccm.161.supplement_3.ats600"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Stagg HR, Zenner D, Harris RJ, Mu\u00f1oz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection. Ann Intern Med 161: 419, 2014.","DOI":"10.7326\/M14-1019"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Wang P, Pradhan K, Zhong X, Ma X. Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B 6: 384-392, 2016.","DOI":"10.1016\/j.apsb.2016.07.014"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Vilholm OJ, Christensen AA, Zedan AH, Itani M. Drug-induced peripheral neuropathy. Basic Clin Pharmacol Toxicol 115: 185-192, 2014.","DOI":"10.1111\/bcpt.12261"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 281: 1014-1018, 1999.","DOI":"10.1001\/jama.281.11.1014"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Peloquin CA, Jaresko GS, Yong CL, Keung ACF, Bulpitt AE, Jelliffe RW. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother 41: 2670-2679, 1997.","DOI":"10.1128\/AAC.41.12.2670"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med 361: 62-72, 2009.","DOI":"10.1056\/NEJMra0801327"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Oshima Y. Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration. Intern Med 50: 845-853, 2011.","DOI":"10.2169\/internalmedicine.50.4484"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Panganiban LR, Makalinao IR, Corte-Maramba NP. Rhabdomyolysis in isoniazid poisoning. J Toxicol Clin Toxicol 39: 143-151, 2001.","DOI":"10.1081\/CLT-100103830"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Blowey DL, Johnson D, Verjee Z. Isoniazid-associated rhabdomyolysis. Am J Emerg Med 13: 543-544, 1995.","DOI":"10.1016\/0735-6757(95)90168-X"},{"key":"13","unstructured":"13. Ey\u00fcbo\u011flu T, Derin\u00f6z O. Rhabdomyolysis due to isoniazid poisoning resulting from the use of intramuscular pyridoxine. Turk J Pediatr 55: 328-330, 2013."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cronkright PJ, Szymaniak G. Isoniazid and rhabdomyolysis. Ann Intern Med 110: 945, 1989.","DOI":"10.7326\/0003-4819-110-11-945_1"},{"key":"15","unstructured":"15. Liu P, Zheng H, Yuan W, Nie R, Wang J. Isoniazid-induced rhabdomyolysis in a patient with chronic heart failure: a case report. Chin Med J (Engl) 123: 502-504, 2010."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30: 239-245, 1981.","DOI":"10.1038\/clpt.1981.154"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Varallo FR, Planeta CS, Herdeiro MT, Mastroianni P de C. Imputation of adverse drug reactions: causality assessment in hospitals. PLoS One 12: e0171470, 2017.","DOI":"10.1371\/journal.pone.0171470"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kim YG, Shin JG, Shin SG, et al. Decreased acetylation of isoniazid in chronic renal failure. Clin Pharmacol Ther 54: 612-620, 1993.","DOI":"10.1038\/clpt.1993.198"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Federico P, Rosanna M, Missimo B, Giovanni T, Mario F. Isoniazid and its hydrazine metabolite in patients with tuberculosis. Clin Drug Investig 17: 145-154, 1999.","DOI":"10.2165\/00044011-199917020-00009"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Arnold PA, Guglielmo BJ, Hollander H. Severe hypersensitivity reaction upon rechallenge with trimethoprim-sulfamethoxazole in a patient with AIDS. Drug Intell Clin Pharm 22: 43-45, 1988.","DOI":"10.1177\/106002808802200110"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Compton MR, Crosby DL. Rhabdomyolysis associated with azathioprine hypersensitivity syndrome. Arch Dermatol 132: 1254-1255, 1996.","DOI":"10.1001\/archderm.1996.03890340120029"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Rahman Z, Weinberg J, Scheinfeld N. Minocycline hypersensitivity syndrome manifesting with rhabdomyolysis. Int J Dermatol 41: 530-531, 2002.","DOI":"10.1046\/j.1365-4362.2002.15636.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kong Q, Sang H, Zhang M, et al. Rhabdomyolysis associated with roxithromycin hypersensitivity syndrome. Indian J Dermatol Venereol Leprol 78: 197-199, 2012.","DOI":"10.4103\/0378-6323.93645"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Huang LY, Lin CM, Chiou CC, Lin WS, Cheng SM. Rhabdomyolysis as a potential complication of carbamazepine-induced toxic epidermal necrolysis. Clin Biochem 45: 1531-1532, 2012.","DOI":"10.1016\/j.clinbiochem.2012.06.008"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kellett S, Cock C. A case of drug reaction with eosinophilia and systemic symptoms. Case Rep Med 2012: 705190, 2012.","DOI":"10.1155\/2012\/705190"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Schirris TJJ, Renkema GH, Ritschel T, et al. Statin-induced myopathy is associated with mitochondrial complex III inhibition. Cell Metab 22: 399-407, 2015.","DOI":"10.1016\/j.cmet.2015.08.002"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Lee KK, Fujimoto K, Zhang C, et al. Isoniazid-induced cell death is precipitated by underlying mitochondrial complex i dysfunction in mouse hepatocytes. Free Radic Biol Med 65: 584-594, 2013.","DOI":"10.1016\/j.freeradbiomed.2013.07.038"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/16\/57_0463-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T14:28:42Z","timestamp":1570890522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/16\/57_0463-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,15]]},"references-count":27,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0463-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,15]]}}}